An innovative clinical trial led by Tang-Du Hospital is set to evaluate a surgical approach for early-stage non-small cell lung cancer (NSCLC) that avoids intubation. This trial, currently not recruiting, will focus on non-intubated video-assisted thoracic surgery with spontaneous breathing (NIVATS). The study aims to assess safety, performance, and potential patient outcomes.
Publication Date: January 10, 2026
In this article
What changed?
This newly announced randomized clinical trial aims to explore whether avoiding intubation during video-assisted thoracic surgery (VATS) can improve outcomes for NSCLC patients in the early stages of the disease. This approach allows patients to breathe spontaneously, potentially reducing procedure-associated stresses and recovery time.
Although still in the planning phase, the trial represents a significant step forward in tailoring interventions for lung cancer patients to improve safety and efficacy.
Who should care?
The trial is highly relevant for healthcare professionals, clinical researchers, and regulators focused on improving minimally invasive techniques for lung cancer treatment. Relevant stakeholders include oncology specialists, thoracic surgeons, and clinical trial designers who are monitoring emerging alternatives to existing standards of care for NSCLC management.
Details on NIVATS
What is NIVATS?
NIVATS, or non-intubated video-assisted thoracic surgery, is a minimally invasive procedure conducted without intubating the patient under general anesthesia. Instead, patients breathe spontaneously during the operation. This technique may potentially reduce the risk of intubation-associated complications, such as airway trauma or prolonged recovery.
Why does it matter?
Early-stage NSCLC patients could benefit from less invasive approaches, as these techniques may lessen the overall physical burden of surgery. NIVATS aligns with modern surgical goals by focusing on enhancing patient experience and recovery outcomes without compromising safety or efficacy.
Current status
As of January 10, 2026, the trial is not yet open for recruitment, with Tang-Du Hospital listed as the sponsor. Once participants are enlisted, the study will provide critical data to inform whether this technique offers significant advantages over conventional intubated modalities.
How will it be evaluated?
The trial will assess the safety and performance of the NIVATS procedure, with particular attention placed on improving perioperative management and post-surgical recovery for patients with clinical stage T1 NSCLC.
FAQ
- What is NSCLC?
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for the majority of cases. - Who is eligible for this trial?
Patients with suspected NSCLC at clinical stage T1, pending full recruitment and enrollment criteria details. - What are the potential benefits of NIVATS?
NIVATS may reduce recovery time, decrease anesthesia-related risks, and improve patient comfort compared to traditional approaches.
Conclusion
This trial signals a shift toward enhancing surgical approaches for early-stage NSCLC. With the potential to improve clinical outcomes, it emphasizes the ongoing progress in minimally invasive lung cancer treatment techniques. Stakeholders are encouraged to monitor recruitment updates for participation opportunities.
Disclaimer
This information is provided for professional and educational purposes only. It is not intended as regulatory or legal advice.
Announcement Link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07327736?term=medical+device